The SARS-CoV-2 pandemic has posed an unprecedented challenge for governments. Questions regarding the most effective interventions to reduce […]
It is hoped that findings from the NIHR-funded trial will help better inform treatment decisions
The move gives the French drug giant access to Kiadis’ natural killer cell technology platform
The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive […]
Updated Date: Fri, 23 Oct 2020 00:00:00 EDT
Updated Date: Fri, 23 Oct 2020 00:00:00 EDT
Updated Date: Fri, 23 Oct 2020 00:00:00 EDT
Updated Date: Fri, 23 Oct 2020 00:00:00 EDT
Updated Date: Fri, 23 Oct 2020 00:00:00 EDT